Richard Stanley Bedlack

Richard Stanley Bedlack

Professor of Neurology

External Address: 
932 Morreene Rd Room234, Durham, NC 27705
Internal Office Address: 
Duke Box 3333, Durham, NC 27710
Phone: 
919.668.2839

Overview

1. Investigator-initiated and multi-center clinical trials testing new treatments for amyotrophic lateral sclerosis and diabetic neuropathy.

2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.

3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.

Education & Training

  • EMG Fellow, Medicine, Duke University 1999 - 2000

  • Neurology Resident, Medicine, Duke University 1996 - 1999

  • Medical Intern, Medicine, Duke University 1995 - 1996

  • M.D., University of Connecticut 1995

  • Ph.D., University of Connecticut 1995

Selected Grants

COMBAT-ALS awarded by (Principal Investigator). 2020 to 2022

ALS Telemedicine awarded by (Principal Investigator). 2020 to 2021

The Duke ALS Association Certified Center awarded by (Principal Investigator). 2018 to 2021

ALS Telemedicine awarded by (Principal Investigator). 2018 to 2020

Integrated Genomics in Clinical ALS (GTAC) awarded by Columbia University (Principal Investigator). 2016 to 2019

CYTO-5022 awarded by (Principal Investigator). 2017 to 2019

Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami (Principal Investigator). 2014 to 2019

Retigabine and or Ezogabine in ALS awarded by (Principal Investigator). 2015 to 2018

Neuraltus NP001 awarded by (Principal Investigator). 2016 to 2018

Pages

Mitsumoto, Hiroshi, et al. “Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener, Apr. 2020, pp. 1–10. Pubmed, doi:10.1080/21678421.2020.1746810. Full Text

Fournier, Christina N., et al. “Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).Jama Neurol, vol. 77, no. 4, Apr. 2020, pp. 480–88. Pubmed, doi:10.1001/jamaneurol.2019.4490. Full Text

Bedlack, Rick. “ALSUntangled 48: Perampanel (Fycompa).Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 5–6, Aug. 2019, pp. 453–56. Pubmed, doi:10.1080/21678421.2019.1573850. Full Text

Bedlack, R. S., et al. “Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial.Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 3–4, May 2019, pp. 285–93. Pubmed, doi:10.1080/21678421.2018.1556698. Full Text

Bedlack, Richard. “ALSUntangled No. 47: RT001.Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 3–4, May 2019, pp. 294–97. Pubmed, doi:10.1080/21678421.2018.1549531. Full Text

ALSUntangled Group, Richard, and Richard Bedlack. “ALSUntangled 46: penicillin G/hydrocortisone.Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 1–2, Feb. 2019, pp. 126–31. Pubmed, doi:10.1080/21678421.2018.1512704. Full Text

Statland, Jeffrey M., et al. “Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.Muscle Nerve, vol. 59, no. 2, Feb. 2019, pp. 201–07. Pubmed, doi:10.1002/mus.26335. Full Text

Bedlack, R., et al. “ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors.” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Jan. 2019. Scopus, doi:10.1080/21678421.2019.1690519. Full Text

Woolley, Susan, et al. “Corrigendum to "Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients".Behav Neurol, vol. 2019, 2019, p. 6704740. Pubmed, doi:10.1155/2019/6704740. Full Text

Pages

Bedlack, Richard S., et al. “Scrutinizing enrollment in ALS clinical trials: Room for improvement?Neurology, vol. 70, no. 11, LIPPINCOTT WILLIAMS & WILKINS, 2008, pp. A344–A344.

Bedlack, R. S., and S. Torres. “Multifocal motor neuropathy with upper motor neuron signs.” Muscle & Nerve, vol. 34, no. 4, JOHN WILEY & SONS INC, 2006, pp. 514–514.

Bedlack, R. S., et al. “Apolipoprotein E genotype is a risk factor for diabetic neuropathy.” Annals of Neurology, vol. 52, no. 6, WILEY-LISS, 2002, pp. 866–866.

Gross, E., et al. “Fluorescent imaging of membrane potential components.” Analytical Use of Fluorescent Probes in Oncology, edited by E. Kohen and J. G. Hirschberg, vol. 286, PLENUM PRESS DIV PLENUM PUBLISHING CORP, 1996, pp. 249–56.

BEDLACK, R. S., et al. “ENDOGENOUS ELECTRIC-FIELDS WITHIN THE NEURONAL PLASMALEMMA - NONUNIFORMITIES SUGGESTING DIFFERENTIAL VOLTAGE-DEPENDENCE.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.

GROSS, E., et al. “DUAL-WAVELENGTH RATIOMETRIC FLUORESCENCE MEASUREMENT OF THE MEMBRANE DIPOLE POTENTIAL.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.

BEDLACK, R. S., et al. “ELECTRIC FIELD-BIASED N1E-115 GROWTH CONE FILOPODIAL PROTRUSIONS ARE INHIBITED BY VERAPAMIL.” Biophysical Journal, vol. 64, no. 2, BIOPHYSICAL SOCIETY, 1993, pp. A101–A101.